A response to the study by Hyldgaard et al
- PMID: 36599428
- PMCID: PMC11181132
- DOI: 10.1111/resp.14449
A response to the study by Hyldgaard et al
Conflict of interest statement
CONFLICTS OF INTEREST
Akihiro Shiroshita: None declared; Peter F. Rebeiro: Funding from NIH (money paid to institution); Consulting for Gilead & Janssen (money paid to individual).
Comment on
-
Immunomodulatory treatment in unclassifiable interstitial lung disease: A retrospective study of treatment response.Respirology. 2023 Apr;28(4):373-379. doi: 10.1111/resp.14409. Epub 2022 Nov 13. Respirology. 2023. PMID: 36372786
References
-
- Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive me. Epidemiology. 2000;11:561–70. - PubMed
-
- Brown AW. Unclassifiable interstitial lung disease: time to shrink the black box. Ann Am Thorac Soc. 2018;15:806–7. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources